Skip to main content

Advertisement

SpringerLink
Log in

Cytokine-Induced Autoimmune Disorders

  • Review Articles
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Cytokines are now commonly used in the treatment of many conditions, especially cancer, haematological malignancies and chronic viral hepatitis. With some of these cytokines, clinical induction and/or exacerbation of autoimmune manifestations have been observed. This has been the case with interferon-α and interferon-γ, interleukin-2 and some colony-stimulating factors. All known biological and clinical autoimmune features have been observed but thyroid abnormalities have been particularly frequent. Some of these manifestations appear to be related to the effect of these exogenous cytokines on the T helper cell (TH) 1/TH2-cytokine balance and the regulatory properties of these cells. Patients with a history of underlying autoimmune disease or baseline serological abnormalities should be monitored for autoimmunity when treated with certain TH1 or TH2-inducing cytokines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fujita S, Puri RK, Yu ZX, et al. An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin 2. Cancer 1991; 68 (10): 2169–74

    PubMed  CAS  Google Scholar 

  2. Haddad J, Deny P, Munz Gotheil C, et al. Lymphocytic sialadenitis of Sjogren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339 (8789): 321–3

    PubMed  CAS  Google Scholar 

  3. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327 (21): 1490–5

    PubMed  CAS  Google Scholar 

  4. Ferri C, Greco F, Longombardo G, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991; 34 (12): 1606–10

    PubMed  CAS  Google Scholar 

  5. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132 (5): 587–93

    PubMed  CAS  Google Scholar 

  6. Vialettes B, Guillerand MA, Viens P, et al. Incidence rate and risk factors for thyroid dysfunction during recombinant inter-leukin-2 therapy in advanced malignancies. Acta Endocrinol 1993; 129 (1): 31–8

    PubMed  CAS  Google Scholar 

  7. Garcia Buey L, Garcia Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108 (6): 1770–7

    PubMed  CAS  Google Scholar 

  8. Miossec P. Acting on the cytokine balance to control autoimmunity and chronic inflammation. Eur Cytokine Netw 1993; 4: 245–51

    PubMed  CAS  Google Scholar 

  9. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145–73

    PubMed  CAS  Google Scholar 

  10. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991; 12: 256–7

    PubMed  CAS  Google Scholar 

  11. Chomarat P, Rissoan M-C, Banchereau J, et al. Interferon γ inhibits interleukin-10 production by monocytes. J Exp Med 1993; 177:523–7

    PubMed  CAS  Google Scholar 

  12. Kapsenberg ML, Wierenga EA, Van Der Heijden FL, et al. Atopic dermatitis and CD4+ atopen-specific TH2 lymphocytes. Eur J Dermatol 1992; 8: 601–7

    Google Scholar 

  13. Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178: 87–99

    PubMed  CAS  Google Scholar 

  14. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254: 277–9

    PubMed  CAS  Google Scholar 

  15. Hess AD, Jones RJ, Morris LE, et al. Autologous graft-versus-host disease: a novel approach for antitumor immunotherapy. Hum Immunol 1992; 34 (3): 219–24

    PubMed  CAS  Google Scholar 

  16. Daynes RA, Araneo BA, Dowell TA, et al. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med 1990; 171: 979–96

    PubMed  CAS  Google Scholar 

  17. Del Prete GF, De Carli M, Mastromauro C, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88: 346–50

    PubMed  Google Scholar 

  18. Gonzalo JA, Cuende E, Ales Martinez JE, et al. Interleukin-2: a possible trigger for autoimmunity. Int Arch Allergy Immunol 1992; 97 (4): 251–7

    PubMed  CAS  Google Scholar 

  19. Kroemer G, Martinez C. Interleukin-2, a pro-autoimmune lymphokine that interferes with post-deletional tolerance. Semin Immunol 1992; 4 (3): 167–79

    PubMed  CAS  Google Scholar 

  20. Nathan CF. Coordinate actions of growth factors in monocytes/ macrophages. In: Sporn MB, Roberts AB, editors. Peptide growth factors and their receptors II. Berlin: Springer-Verlag, 1990: 427–53

    Google Scholar 

  21. Becker JC, Dummer R, Schwinn A, et al. Circulating intercellular adhesion molecule 1 in melanoma patients: induction by interleukin 2 therapy. J Immunother 1992; 12 (2): 147–50

    PubMed  CAS  Google Scholar 

  22. Baars JW, de Boer JP, Wagstaff J, et al. Interleukin 2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia. Br J Haematol 1992; 82 (2): 295–301

    PubMed  CAS  Google Scholar 

  23. Punt KC, Jansen RL, De Mulder PH, et al. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study. J Immunother 1992; 12 (4): 277–84

    PubMed  CAS  Google Scholar 

  24. Huynh HK, Oger J, Dorovini Zis K. Interferon-beta down-regulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol 1995; 60 (1–2): 63–73

    PubMed  CAS  Google Scholar 

  25. Brod SA, Marshall GD Jr, Henninger EM, et al. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996; 46 (6): 1633–8

    PubMed  CAS  Google Scholar 

  26. Realdi G, Fattovich G, Pastore G, et al. Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. J Hepatol 1990; 11 Suppl. 1: S129–32

    PubMed  Google Scholar 

  27. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24 (1): 38–47

    PubMed  CAS  Google Scholar 

  28. Hirashima N, Mizokami M, Orito E, et al. Chronic hepatitis C complicated by Coombs-negative hemolytic anemia during interferon treatment. Intern Med 1994; 33 (5): 300–2

    PubMed  CAS  Google Scholar 

  29. Radin AI, Buckley P, Duffy TP. Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia. Hematol Pathol 1991; 5 (2): 83–8

    PubMed  CAS  Google Scholar 

  30. McSweeney EN, Giles FJ, Worman CP, et al. Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia. Br J Haematol 1993; 85 (1): 77–83

    PubMed  CAS  Google Scholar 

  31. Siciliano R, Trovato BA, Seminara G, et al. Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Ann Ital Med Int 1995; 10 (3): 193–4

    PubMed  CAS  Google Scholar 

  32. Shrestha R, McKinley C, Bilir BM, et al. Possible idiopathic thrombocytopenic purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1995; 90 (7): 1146–7

    PubMed  CAS  Google Scholar 

  33. Murakami CS, Zeller K, Bodenheimer HC Jr, et al. Idiopathic thrombocytopenic purpura during interferon alpha 2B treatment for chronic hepatitis. Am J Gastroenterol 1994; 89 (12): 2244–5

    PubMed  CAS  Google Scholar 

  34. Durand JM, Lefevre P, Telle H, et al. Thrombocytopenic purpura and hepatitis C virus infection [letter]. Haematologica 1993; 78 (2): 135

    PubMed  CAS  Google Scholar 

  35. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol 1994; 21 (2): 350–2

    PubMed  CAS  Google Scholar 

  36. Wandl UB, Nagel Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65 (1): 70–4

    PubMed  CAS  Google Scholar 

  37. Bojic I, Lilic D, Radojcic C, et al. Deterioration of mixed cryoglobulinemia during treatment with interferon alpha 2a. J Gastroenterol 1994; 29 (3): 369–71

    PubMed  CAS  Google Scholar 

  38. Harle JR, Disdier P, Pelletier J, et al. Dramatic worsening of hepatitis C virus-related cryoglobulinemia subsequent to treatment with interferon alfa [letter]. JAMA 1995; 274 (2): 126

    PubMed  CAS  Google Scholar 

  39. Scheibenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 1994; 30A (8): 1209–11

    PubMed  CAS  Google Scholar 

  40. Georgetson MJ, Yarze JC, Lalos AT, et al. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993; 88 (10): 1756–8

    PubMed  CAS  Google Scholar 

  41. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma: results of immunohistologic investigations. Arch Dermatol 1990; 126(3): 351–5

    PubMed  CAS  Google Scholar 

  42. Fattovich G, Betterle C, Brollo L, et al. Autoantibodies during alpha interferon therapy for chronic hepatitis B. J Med Virol 1991; 34 (2): 132–5

    PubMed  CAS  Google Scholar 

  43. Fattovich G, Betterle C, Brollo L, et al. Induction of autoantibodies during alpha interferon treatment in chronic hepatitis B. Arch Virol Suppl 1992; (4): 291–3

    PubMed  CAS  Google Scholar 

  44. Kirsner RS, Anhalt GJ, Kerdel FA. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol 1995; 132 (3): 474–8

    PubMed  CAS  Google Scholar 

  45. Wandl UB, Kloke O, Nagel Hiemke M, et al. Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pre-treated patients with Ph-positive chronic myelogenous leukaemia. Br J Haematol 1992; 81 (4): 516–9

    PubMed  CAS  Google Scholar 

  46. Silvestri F, Virgolini L, Mazzolini A, et al. Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons. Haematologica 1994; 79 (4): 367–70

    PubMed  CAS  Google Scholar 

  47. Nagayama Y, Ohta K, Tsuruta M, et al. Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J 1994; 41 (5): 565–72

    PubMed  CAS  Google Scholar 

  48. Vallisa D, Cavanna L, Berte R, et al. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 1995; 93 (1): 31–5

    PubMed  CAS  Google Scholar 

  49. Lisker Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102 (6): 2155–60

    PubMed  CAS  Google Scholar 

  50. Lim SH, Callaghan T, Goldstone AH. Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion. Acta Haematol 1991; 85 (1): 49–50

    PubMed  CAS  Google Scholar 

  51. Chung YH, Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am J Gastroenterol 1993; 88 (2): 244–7

    PubMed  CAS  Google Scholar 

  52. Monig H, Hauschild A, Lange S, et al. Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma. Clin Investig 1994; 72 (12): 975–8

    PubMed  CAS  Google Scholar 

  53. Gisslinger H, Gilly B, Woloszczuk W, et al. Thyroid autoimmunity and hypothyroidism during long term treatment with recombinant interferon alpha. Clin Exp Immunol 1992; 90 (3): 363–7

    PubMed  CAS  Google Scholar 

  54. Waguri M, Hanafusa T, Itoh N, et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract 1994; 23 (1): 33–6

    PubMed  CAS  Google Scholar 

  55. Krug J, Fritzsch J, Aust G. Induction of insulin antibodies and insulin allergy under alpha interferon treatment of renal cell carcinoma in a patient with insulin-treated diabetes mellitus: a case report. Int Arch Allergy Immunol 1995; 106 (2): 169–72

    PubMed  CAS  Google Scholar 

  56. Schilling PJ, Kurzrock R, Kantarjian H, et al. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991; 68 (7): 1536–7

    PubMed  CAS  Google Scholar 

  57. Flores A, Olive A, Feliu E, et al. Systemic lupus erythematosus following interferon therapy [letter]. Br J Rheumatol 1994; 33 (8): 787

    PubMed  CAS  Google Scholar 

  58. Tolaymat A, Leventhal B, Sakarcan A, et al. Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 1992; 120 (3): 429–32

    PubMed  CAS  Google Scholar 

  59. Conlon KC, Urba WJ, Smith JWD, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-inter-feron therapy. Cancer 1990; 65 (10): 2237–42

    PubMed  CAS  Google Scholar 

  60. O’Connell PG, Gerber LH, Digiovanna JJ, et al. Arthritis in patients with psoriasis treated with gamma interferon. J Rheumatol 1992; 19 (1): 80–2

    PubMed  Google Scholar 

  61. Cleveland MG, Mallory SB. Incomplete Reiter’s syndrome induced by systemic interferon alpha treatment. J Am Acad Dermatol 1993; 29 (5 Pt 1): 788–9

    PubMed  CAS  Google Scholar 

  62. Matsuya M, Abe T, Tosaka M, et al. The first case of polymyositis associated with interferon therapy. Intern Med 1994; 33 (12): 806–8

    PubMed  CAS  Google Scholar 

  63. Esteva Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer 1995; 76 (7): 1219–23

    PubMed  CAS  Google Scholar 

  64. Perez A, Perella M, Pastor E, et al. Myasthenia gravis induced by alpha interferon therapy. Am J Hematol 1995; 49 (4): 365–6

    PubMed  CAS  Google Scholar 

  65. Batocchi AP, Evoli A, Servidei S, et al. Myasthenia gravis during interferon alfa therapy. Neurology 1995; 45 (2): 382–3

    PubMed  CAS  Google Scholar 

  66. Piccolo G, Franciotta D, Versino M, et al. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment [letter]. J Neurol Neurosurg Psychiatry 1996; 60 (3): 348

    PubMed  CAS  Google Scholar 

  67. Mase G, Zorzon M, Biasutti E, et al. Development of myasthenia gravis during interferon alpha treatment for anti HCV positive chronic hepatitis. J Neurol Neurosurg Psychiatry 1996; 60 (3): 348–9

    PubMed  CAS  Google Scholar 

  68. Schwarzer A, Schulze E, Leiblein S, et al. Guillain Barré syndrome, a possible side effect of buffy coat transfusion and IFN alpha therapy in relapsed CML after bone marrow transplantation [letter]. Ann Oncol 1995; 6 (6): 617

    PubMed  CAS  Google Scholar 

  69. Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis exacerbated by alpha interferon. Ann Intern Med 1992; 116 (1): 51–3

    PubMed  CAS  Google Scholar 

  70. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102 (4 Pt 1): 1406–8

    PubMed  CAS  Google Scholar 

  71. Marcellin P, Colin JF, Boyer N, et al. Fatal exacerbation of chronic hepatitis B induced by recombinant alpha interferon [letter]. Lancet 1991; 338 (8770): 828

    PubMed  CAS  Google Scholar 

  72. Czaja AJ. Autoimmune hepatitis and viral infection. Gastroenterol Clin North Am 1994; 23 (3): 547–66

    PubMed  CAS  Google Scholar 

  73. Ferri C, Longombardo G, La Civita L, et al. Hepatitis C virus, autoimmune liver disease and cryoglobulinaemic hepatitis. J Hepatol 1992; 16 (1–2): 242–3

    PubMed  CAS  Google Scholar 

  74. Heintges T, Niederau C. Differentiation between autoimmune hepatitis and hepatitis C virus-related liver disease. Z Gastroenterol 1993; 31 (5): 285–8

    PubMed  CAS  Google Scholar 

  75. Muratori L, Lenzi M, Cataleta M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21 (2): 199–203

    PubMed  CAS  Google Scholar 

  76. Cianciara J, Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig Dis Sci 1995; 40 (8): 1842–4

    PubMed  CAS  Google Scholar 

  77. Ariad S, Song E, Cohen R, et al. Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes. Mol Biother 1992; 4 (3): 139–42

    PubMed  CAS  Google Scholar 

  78. D’Amico E, Paroli M, Fratelli V, et al. Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Dig Dis Sci 1995; 40 (10): 2113–6

    PubMed  Google Scholar 

  79. Maeda T, Onishi S, Miura T, et al. Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C. Dig Dis Sci 1995; 40 (6): 1226–30

    PubMed  CAS  Google Scholar 

  80. Browett PJ, Nelson J, Tiwari S, et al. Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukaemia post-allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14 (4): 641–4

    PubMed  CAS  Google Scholar 

  81. Dousset B, Conti F, Houssin D, et al. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver transplant recipients. N Engl J Med 1994; 330 (16): 1160–1

    PubMed  CAS  Google Scholar 

  82. Gadano AC, Mosnier JF, Durand F, et al. Alpha interferon induced rejection of a hepatitis C virus infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 1995; 59 (11): 1627–9

    PubMed  CAS  Google Scholar 

  83. Magnone M, Holley JL, Shapiro R, et al. Interferon alpha induced acute renal allograft rejection. Transplantation 1995; 59 (7): 1068–70

    PubMed  CAS  Google Scholar 

  84. Min AD, Bodenheimer HC Jr. Does interferon precipitate rejection of liver allografts? Hepatology 1995; 22 (4 Pt 1): 1333–5

    PubMed  CAS  Google Scholar 

  85. Sacchi S, Kantarjian H, O’Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13 (9): 2401–7

    PubMed  CAS  Google Scholar 

  86. Imagawa A, Itoh N, Hanafusa T, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 1995; 80 (3): 922–6

    PubMed  CAS  Google Scholar 

  87. Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81 (5): 1132–6

    PubMed  CAS  Google Scholar 

  88. Ferri C, Marzo E, Longombardo G, et al. Alpha interferon in the treatment of mixed cryoglobulinaemia patients. Eur J Cancer 1991; 27 Suppl. 4: 81S–2S

    Google Scholar 

  89. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676–80

    PubMed  CAS  Google Scholar 

  90. Ballmer Weber BK, Dummer R, Kung E, et al. Interleukin-2 induced increase of vascular permeability without decrease of the intravascular albumin pool. Br J Cancer 1995; 71 (1): 78–82

    PubMed  CAS  Google Scholar 

  91. Ogilvie AC, Baars JW, Eerenberg AJ, et al. A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high dose interleukin-2. Br J Cancer 1994; 69 (3): 596–8

    PubMed  CAS  Google Scholar 

  92. Lissoni P, Barni S, Cattaneo G, et al. Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. Int J Biol Markers 1990; 5 (4): 195–7

    PubMed  CAS  Google Scholar 

  93. Gaspari AA. Autoimmunity as a complication of interleukin-2 immunotherapy: many unanswered questions [comment]. Arch Dermatol 1994; 130 (7): 894–8

    PubMed  CAS  Google Scholar 

  94. Massarotti EM, Liu NY, Mier J, et al. Chronic inflammatory arthritis after treatment with high dose interleukin-2 for malignancy. Am J Med 1992; 92 (6): 693–7

    PubMed  CAS  Google Scholar 

  95. Finger DR, Plotz PH, Heywood G. Myositis following treatment with high dose interleukin 2 for malignancy [letter]. J Rheumatol 1995; 22 (11): 2188

    PubMed  CAS  Google Scholar 

  96. Schwartzentruber DJ, White DE, Zweig MH, et al. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 1991; 68: 2384–90

    PubMed  CAS  Google Scholar 

  97. Perez R, Padavic K, Krigel R, et al. Antierythrocyte autoanti-body formation after therapy with interleukin 2 and gamma interferon. Cancer 1991; 67 (10): 2512–7

    PubMed  CAS  Google Scholar 

  98. Puduvalli VK, Sella A, Austin SG, et al. Carpal tunnel syndrome associated with interleukin 2 therapy. Cancer 1996; 77 (6): 1189–92

    PubMed  CAS  Google Scholar 

  99. Dummer R, Miller K, Eilles C, et al. The skin: an immunoreactive target organ during interleukin 2 administration? Dermatologica 1991; 183 (2): 95–9

    PubMed  CAS  Google Scholar 

  100. Baars JW, Wagstaff J, Hack CE, et al. Angioneurotic oedema and urticaria during therapy with interleukin 2 (IL 2). Ann Oncol 1992; 3 (3): 243–4

    PubMed  CAS  Google Scholar 

  101. Baars JW, Coenen JL, Wagstaff J, et al. Lobular panniculitis after subcutaneous administration of interleukin 2 (IL-2), and its exacerbation during intravenous therapy with IL-2. Br J Cancer 1992; 66 (4): 698–9

    PubMed  CAS  Google Scholar 

  102. Heinzer H, Huland E, Huland H. Adverse reaction to contrast material in a patient treated with local interleukin 2 [letter]. Am J Roentgenol 1992; 158 (6): 1407

    CAS  Google Scholar 

  103. Heywood GR, Rosenberg SA, Weber JS. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. J Natl Cancer Inst 1995; 87 (12): 915–22

    PubMed  CAS  Google Scholar 

  104. Zukiwski AA, David CL, Coan J, et al. Increased incidence of hypersensitivity to iodine-containing radiographie contrast media after interleukin-2 administration. Cancer 1990; 65 (7): 1521–4

    PubMed  CAS  Google Scholar 

  105. Puett DW, Fuchs HA. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine-activated killer cells for renal cell carcinoma. J Rheumatol 1994; 21 (4): 752–3

    PubMed  CAS  Google Scholar 

  106. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39 (3): 285–94

    PubMed  CAS  Google Scholar 

  107. Kung AW, Jones BM, Lai CL. Effects of interferon-gamma therapy on thyroid function, T-lymphocyte subpopulations and induction of autoantibodies. J Clin Endocrinol Metab 1990; 71 (5): 1230–4

    PubMed  CAS  Google Scholar 

  108. Bobbio Pallavicini E, Valsecchi C, Tacconi F, et al. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis 1995; 12 (2): 140–2

    PubMed  CAS  Google Scholar 

  109. Sampaio EP, Moreira AL, Sarno EN, et al. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175(6): 1729–37

    PubMed  CAS  Google Scholar 

  110. Seitz M, Franke M, Kirchner H. Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma. Ann Rheum Dis 1988; 47: 642–4

    PubMed  CAS  Google Scholar 

  111. Cannon GW, Emkey RD, Denes A, et al. Prospective 5-year followup of recombinant interferon-gamma in rheumatoid arthritis. J Rheumatol 1993; 20 (11): 1867–73

    PubMed  CAS  Google Scholar 

  112. Myers LW, Ellison GW. The peculiar difficulties of therapeutic trials for multiple sclerosis. Neurol Clin 1990; 8 (1): 119–41

    PubMed  CAS  Google Scholar 

  113. Hoshina Y, Moriuchi J, Nakamura Y, et al. CD4+ T cell mediated leukopenia of Felty’s syndrome successfully treated with granulocyte colony stimulating factor and methotrexate. Arthritis Rheum 1994; 37 (2): 298–9

    PubMed  CAS  Google Scholar 

  114. de Vries EG, Willemse PH, Biesma B, et al. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy [letter]. Lancet 1991; 338 (8765): 517–8

    PubMed  Google Scholar 

  115. Hayat SQ, Hearth Holmes M, Wolf RE. Flare of arthritis with successful treatment of Felty’s syndrome with granulocyte colony stimulating factor (GCSF). Clin Rheumatol 1995; 14 (2): 211–2

    PubMed  CAS  Google Scholar 

  116. Kiely PD, Bruckner FE. Acute arthritis following interferon alpha therapy. Br J Rheumatol 1994; 33 (5): 502–3

    PubMed  CAS  Google Scholar 

  117. Vidarsson B, Geirsson AJ, Onundarson PT. Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony stimulating factor for Felty’s syndrome. Am J Med 1995; 98 (6): 589–91

    PubMed  CAS  Google Scholar 

  118. McMullin MF, Finch MB. Felty’s syndrome treated with rhG-CSF associated with flare of arthritis and skin rash. Clin Rheumatol 1995; 14 (2): 204–8

    PubMed  CAS  Google Scholar 

  119. Yasuda M, Kihara T, Wada T, et al. Granulocyte colony stimulating factor induction of improved leukocytopenia with inflammatory flare in a Felty’s syndrome patient. Arthritis Rheum 1994 37 (1): 145–6

    PubMed  CAS  Google Scholar 

  120. Storek J, Glaspy JA, Grody WW, et al. Adult onset cyclic neutropenia responsive to cyclosporine therapy in a patient with ankylosing spondylitis. Am J Hematol 1993; 43 (2): 139–43

    PubMed  CAS  Google Scholar 

  121. Bhalla K, Ross R, Jeter E, et al. G-CSF improves granulocytopenia in Felty’s syndrome without flare-up of arthritis. Am J Hematol 1993; 42 (2): 230–1

    PubMed  CAS  Google Scholar 

  122. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115 (3): 178–83

    PubMed  CAS  Google Scholar 

  123. Miossec P, Chomarat P, Dechanet J. Bypassing the antigen to control rheumatoid arthritis. Immunol Today 1996; 17: 170–3

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Immunology Unit, Departments of Immunology and Rheumatology, Hôpital Edouard Herriot, 69437, Lyon Cedex 03, France

    Pierre Miossec

Authors
  1. Pierre Miossec
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Miossec.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miossec, P. Cytokine-Induced Autoimmune Disorders. Drug-Safety 17, 93–104 (1997). https://doi.org/10.2165/00002018-199717020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199717020-00002

Keywords

Search

Navigation